Kyverna Therapeutics (KYTX) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Surrozen (SRZN) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 99.2% versus a loss of 13.9%. Kyverna Therapeutics is the larger company by market cap ($402.6 million vs $352.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYTX | SRZN |
|---|---|---|
| Share price | $6.51 | $29.99 |
| Market cap | $402.60M | $352.49M |
| 1-day change | +5.34% | +7.22% |
| YTD return | -34.26% | +23.76% |
| 1-year return | -13.93% | +99.22% |
| 5-year return | — | -70.50% |
| EPS (TTM) | $-2.93 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.67 | $37.83 |
| 52-week low | $5.96 | $11.39 |
| Distance from 52-week high | -52.38% | -20.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +366.97% | +61.39% |
| Average volume | 903.83K | 483.28K |
| Shares outstanding | 61.84M | 11.75M |
| Employees | 149 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed KYTX by 113.1 percentage points over the past year.
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
KYTX vs SRZN FAQ
Which is bigger, Kyverna Therapeutics or Surrozen?
Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $402.60M compared with $352.49M for Surrozen (SRZN).
Which stock has performed better over the past year, KYTX or SRZN?
SRZN returned +99.22% over the past 12 months, compared with -13.93% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are Kyverna Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.